Policymakers struggle to apply academic findings because research doesn't specify how to translate evidence into procurement documents. An intermediary is needed to bridge this gap, acting as an in-house consultant to map research to actionable implementation plans for those writing contracts.

Despite being seen as innovation hubs, universities face identical organizational barriers as large corporations. Academics report that internal power structures, cultural inertia, and siloed departments create bottlenecks that prevent them from effectively commercializing novel IP, mirroring corporate struggles.

Philanthropy often addresses symptoms because the market won't pay to solve the root problem. True, lasting progress comes from innovating to create a self-sustaining economic engine around a solution, proving its value in a marketplace where people vote with their money.

A key driver of Sweden's entrepreneurial biotech culture is a law allowing inventors, such as university professors, to personally own the patents from their research. This contrasts with the US model where institutions retain IP rights, giving Swedish academics a direct incentive to commercialize their discoveries.

The current movement towards impact-focused business is not just a trend but a fundamental economic succession. Just as the tech revolution reshaped global industries, the impact revolution is now establishing a new paradigm where companies are valued on their ability to create both profit and positive contributions to society and the planet.

Top academic mentors like MIT's Dr. Robert Langer guide postdocs away from incremental research toward solving major, high-risk problems. This focus on creating significant societal impact, rather than just publishing, serves as the direct catalyst for founding ambitious companies like Vivtex.

The biotech landscape in Southeast Asia has strong scientific talent but lacks a mature 'translation ecosystem' (VCs, experienced operators). Founders must take on the dual role of building their company and simultaneously cultivating the surrounding infrastructure, including talent, partnerships, and public trust.

In nascent markets, product work is inherently tied to solving fundamental human problems. This reality forces a focus on meaningful outcomes like saving lives or reducing poverty, making typical tech vanity metrics feel trivial by comparison.

Airway Therapeutics' CEO founded a CRO to resolve the disconnect between academic research's discovery focus and industry's market-driven goals. This "translator" model aligned incentives and regulatory understanding, fostering more efficient drug development by merging clinical feasibility with commercial targets.